<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Mutation of BRAF is a predominant event in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> with poor prognosis such as <z:hpo ids='HP_0002861'>melanoma</z:hpo> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>BRAF mutation leads to a constitutive activation of <z:chebi fb="0" ids="52290">mitogen</z:chebi> activated protein kinase pathway which is essential for cell proliferation and <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">tumor progression</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Despite tremendous efforts made to target BRAF for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment, the correlation between BRAF mutation and patient survival is still a matter of controversy </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS/PRINCIPAL FINDINGS: Clinical studies on the correlation between BRAF mutation and patient survival were retrieved from MEDLINE and EMBASE databases between June 2002 and December 2011 </plain></SENT>
<SENT sid="4" pm="."><plain>One hundred twenty relevant full text studies were categorized based on study design and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> type </plain></SENT>
<SENT sid="5" pm="."><plain>Publication bias was evaluated for each category and pooled hazard ratio (HR) with 95% confidence interval (CI) was calculated using random or fixed effect meta-analysis based on the percentage of <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Twenty six studies on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (11,773 patients) and four studies on <z:hpo ids='HP_0002861'>melanoma</z:hpo> (674 patients) were included in our final meta-analysis </plain></SENT>
<SENT sid="7" pm="."><plain>The average prevalence of BRAF mutation was 9.6% in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, and 47.8% in <z:hpo ids='HP_0002861'>melanoma</z:hpo> reports </plain></SENT>
<SENT sid="8" pm="."><plain>We found that BRAF mutation increases the risk of mortality in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients for more than two times; HR = 2.25 (95% CI, 1.82-2.83) </plain></SENT>
<SENT sid="9" pm="."><plain>In addition, we revealed that BRAF mutation also increases the risk of mortality in <z:hpo ids='HP_0002861'>melanoma</z:hpo> patients by 1.7 times (95% CI, 1.37-2.12) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: We revealed that BRAF mutation is an absolute risk factor for patient survival in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> and <z:hpo ids='HP_0002861'>melanoma</z:hpo> </plain></SENT>
</text></document>